ArticleOncoimmunology

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma.

David L Bajor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.